newsfilter
← Latest News
Business Wire·

Cybin Announces Closing of $175 Million Registered Direct Offering

Cybin Inc. (Cboe CA: CYBN) (NYSE:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery